medigraphic.com
Academia Mexicana de Neurología, A.C.

2009, Número 1

<< Anterior Siguiente >>

Rev Mex Neuroci 2009; 10 (1)


Tratamiento de padecimientos neuromusculares con inmunoglobulina y plasmaféresis

Porras-Betancourt M

Idioma: Español
Referencias bibliográficas: 86
Paginas: 18-29
Archivo PDF: 90.26 Kb.


RESUMEN

Existen varios padecimientos del sistema nervioso periférico inmunomediados que abarcan alteraciones musculares, de los nervios y la unión entre ambos. Dado el origen inmunológico de dichos padecimientos, el tratamiento se basa en la inmunosupresión y/o la inmunomoduilación. La aplicación de inmunoglobulina intravenosa y el recambio plasmático se consideran dentro del tratamiento de dichas enfermedades como terapias inmunomoduladoras que retrasan la progresión y mejoran la calidad de vida de quienes padecen estos problemas. La presente revisión se enfoca en las indicaciones de la inmunoglobulina intravenosa y el recambio plasmático en padecimientos del sistema nervioso periférico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chitnis T, Khoury SJ. Immunologic neuromuscular disorders. J Allergy Clin Immunol 2003; 111: S659-68.

  2. Kokontis L, Gutmann L. Current treatment of neuromuscular diseases. Arch Neurol 2000; 57: 939-43.

  3. Lehmann HC, Hartung HP, Gerd RH, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders. Part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006; 63: 930-5.

  4. Korach JM, Berger P, Giraud C, Le Perff-Desman C, Chillet P. French Registry Cooperative Group. Role of replacement fluids in the immediate complications of plasma exchange. Intensive Care Med 1998; 24: 452-8.

  5. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, et al. Guidelines on the Use of Therapeutic apheresis in clinical practice-Evidence- Based Approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clinic Apheresis 2007; 22: 106-75.

  6. Assessment of plasmapheresis. Report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 1996; 47: 840-3.

  7. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apheresis 2000; 15: 74-128.

  8. Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096-104.

  9. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome. Ann Neurol 1987; 22: 753-61.

  10. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome. Ann Neurol 1992; 32: 94-7.

  11. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997; 349: 225-30.

  12. Dada MA, Kaplan AA. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement. Ther Apher Dial 2004; 8: 409-12.

  13. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2001: CD001798.

  14. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain- Barré syndrome. Ann Neurol 1997; 41: 298-306.

  15. Haupt WF. Recent advances of therapeutic apheresis in Guillain- Barre syndrome. Ther Apher. 2000; 4: 271-4.

  16. Khalili-Shirazi A, Atkinson P, Gregson N, Hughes RA. Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1993; 46: 245-51.

  17. Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002; 59: S7- S17.

  18. Toyka KV, Gold R. The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology 2003; 60:S2-S7.

  19. Sutton IJ, Winer JB. Immunosuppression in peripheral neuropathy: rationale and reality. Curr Opin Pharmacol 2002; 2: 291-5.

  20. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004(3): CD003906.

  21. Dyck PJ, Daube J, O’Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314: 461-5.

  22. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. Brain 1996; 119: 1055-66.

  23. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838-45.

  24. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338: 1601-7.

  25. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991; 325: 1482-6.

  26. Simovic D, Gorson KC, Ropper AH. Comparison of IgM MGUS and IgG-MGUS polyneuropathy. Acta Neurol Scand1998; 97: 194-200.

  27. Vincent A, Drachman DB. Myasthenia gravis. Adv Neurol 2002; 88: 159-88.

  28. De Baets M, Stassen MH. The role of antibodies in myasthenia gravis. J Neurol Sci 2002; 202: 5-11.

  29. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-8.

  30. National Institutes of Health Consensus Development Conference. The use of therapeutic plasmapheresis for neurological disorders. Transfus Med Rev 1988; 2: 48-53.

  31. Assessment of plasmapheresis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996; 47: 840-3.

  32. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41: 789-96.

  33. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2003(2): CD002277.

  34. SandersDB.Lambert-Eatonmyasthenicsyndrome: clinicaldiagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 1995; 37(Suppl. 1): S63-S73.

  35. Lang B, Waterman S, Pinto A, et al. The role of autoantibodies in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1998; 841: 596-605.

  36. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34: 480-5.

  37. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002; 59(Suppl. 6): S28-S32.

  38. Kazatchkine MD, Kaveri SV. Advances in immunology: immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.

  39. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002; 59(Suppl. 6): S13-S21.

  40. Dalakas MC. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med 1997; 126: 721-30.

  41. Diegel M, Rankin B, Bolen J, Dubois P, Kiener P. Cross linking of Fc receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem 1994; 269: 11409-16.

  42. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227–228.

  43. Ankrust P, Muller F, Svenson M, Nordoy I, Bendtzen K, Froland SS. Administration of intravenous immunoglobulin (IVIg) in vivo down-regulatory effects on the IL-1 system. Clin Exp Immunol 1999; 115: 136-43.

  44. Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998; 121: 159-66.

  45. Damĺs JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001; 38: 187-93.

  46. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35.

  47. Leung DY, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987; 79: 468-72.

  48. Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC. Effect of IVIg in peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effect on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 1994; 71: 309-14.

  49. Blasczyk R, Westhoff V, Grosse-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789-90.

  50. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006; 46: 741-53.

  51. Dalakas MC. Intravenous Immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines Muscle Nerve 1999; 22: 1479-97.

  52. Misra N, Bayry J, Ephrem A, Dasgupta S, et al. Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol 2005; 252[Suppl. 1]: 1-6.

  53. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barre’ syndrome-part II. Muscle Nerve 1995; 18: 154-64.

  54. van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-9.

  55. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC. Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001; 71: 235-8.

  56. Ross MA. Intravenous Immunoglobulin Therapy for Neuromuscular Disorders. Semin Neurol 2007; 27: 340-6.

  57. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in Guillain-Barré syndrome. Lancet 1997; 349: 225- 30.

  58. Dyck PJ, O’Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-41.

  59. Hahn AF. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 1998; 51: S16-S21.

  60. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50: 195-201.

  61. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445-9.

  62. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo controlled, cross-over study. Brain 1996; 119: 1067-77.

  63. Choudhary PP, Hughes RAC. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med 1995; 88: 493– 502.

  64. van Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebocontrolled, crossover study. Neurology 1990; 40: 209-12.

  65. van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol 2002; 1: 491-8.

  66. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 2005; 31: 663-80.

  67. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000; 55: 1256-62.

  68. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001; 124: 145-53.

  69. Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH. Multifocal motor neuropathy: longterm clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002; 125: 1875-86.

  70. Dalakas MC. Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA 2004; 291: 2367-75.

  71. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996; 40: 792-5.

  72. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002; 249: 1370-7.

  73. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin 1g/kg versus 2g/kg: a randomized double blind clinical trial. Arch Neurol 2005; 62: 1689-93.

  74. Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 2005; 252: 114-18.

  75. Fuchs S, Feferman T, Zhu KY, et al. Suppression of Experimental Autoimmune Myasthenia Gravis by Intravenous Immunoglobulin and Isolation of a Disease-Specific IgG Fraction. Ann NY Acad Sci 2007; 1110: 550-8.

  76. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996; 47: 678-83.

  77. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.

  78. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35.

  79. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty five adult patients. Arthritis Rheum 2002; 46: 467-74.

  80. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 712-16.

  81. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56: 323-7.

  82. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002; 58: 326.

  83. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259-62.

  84. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. International Immunopharmacology 2006; 6: 535-42.

  85. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004; 102: 177-93.

  86. Caress JB, Cartwright MS, Donofrio PD, Peacock Jr JE. The clinical features of 16 cases of stroke associated with administration of IGIV. Neurology 2003; 60: 1822- 4.




2020     |     www.medigraphic.com